A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Name: A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Published: 2011
License: Public Domain

Janssen Research & Development, LLC · 2011

ClinicalTrials.gov · Datasets · License: Public Domain · 2011

Open Source ↗

crohn-s-disease ibd inflammatory-bowel-disease

crohn's disease, ibd, colitis, inflammatory bowel disease, ustekinumab, moderately to severely active crohn's disease, tumor necrosis factor, stelara, crohn, crohn's, uniti, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Related documents